Dr. Peter O'Dwyer (IMAGE)
Caption
“Realized through collaboration between ECOG-ACRIN, NCI, and Caris Life Sciences, this public-private partnership represents a methodological, logistical, and collaborative integration of datasets from the historically impactful TAILORx trial to further extend the benefits for breast cancer patients, said ECOG-ACRIN Group Co-Chair Peter J. O’Dwyer, MD. “The advance in personalized medicine afforded in this work, in turn, helps to advance the potential of AI to refine treatment and improve outcomes.”
Credit
ECOG-ACRIN
Usage Restrictions
No restrictions.
License
Public Domain